Effect and safety of antithrombotic therapies for secondary prevention after acute coronary syndrome: a network meta-analysis
Authors Mo FR, Li J, Yan YL, Wu WF, Lai SY
Received 25 February 2018
Accepted for publication 10 August 2018
Published 25 October 2018 Volume 2018:12 Pages 3583—3594
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Georgios D. Panos
Fanrui Mo,1 Juan Li,2 Yuluan Yan,2 Weifeng Wu,1 Shayi Lai2
1Department of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China; 2Department of Cardiology, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, China
Background: Dual antiplatelet therapy is a standard protocol for secondary prevention after acute coronary syndrome, but despite a variety of new dual antithrombotic strategies, there is a dearth of studies evaluating the effects and safety of some popular therapies. This study used a network meta-analysis to compare the efficacy and safety of all available antithrombotic therapies.
Methods: PubMed, MEDLINE, and Cochrane library databases were searched for randomized controlled trials, published up to July 1, 2017, that evaluated the efficacy of antithrombotic therapy in acute coronary syndrome treatment. The primary endpoints were clinically significant bleeding and major bleeding and secondary endpoints were major cardiovascular events, all-cause deaths, cardiac deaths, and myocardial infarction.
Results: Compared with treatment with aspirin + new P2Y12 inhibitor, treatment with aspirin + new P2Y12 inhibitor converted to clopidogrel clinically reduced the risk of major cardiovascular events or significant bleeding (OR: 0.30, 95% credibility interval: 0.12–0.75). Both myocardial infarction risk (OR: 0.82, 95% credibility interval: 0.62–1.09) and major bleeding risk (OR: 0.18, 95% credibility interval: 0.01–1.68) were not significantly different between treatment regimens. There were no significant differences in major cardiovascular events, all-cause deaths, cardiac deaths, myocardial infarction, clinically significant bleeding, and major bleeding risk with rivaroxaban + new P2Y12 inhibitor therapy when compared with aspirin + new P2Y12 inhibitor. Compared with aspirin + clopidogrel, the conversion therapy further reduced the risk of myocardial infarction (OR: 1.81, 95%, credibility interval: 1.01–1.34) without an increased clinical risk of significant bleeding (OR: 0.41, 95%, credibility interval: 0.15–1.07). Treatment with aspirin + new P2Y12 inhibitors reduced all-cause deaths (OR: 0.91, 95% credibility interval: 0.84–0.98) and cardiac death risk (OR: 0.86, 95% credibility interval: 0.79–0.93).
Conclusion: We concluded the following from our study: 1) an aspirin + new P2Y12 inhibitor/clopidogrel conversion treatment strategy was not inferior to aspirin + new P2Y12 inhibitor; 2) compared with aspirin + clopidogrel, the conversion strategy may further reduce the risk of myocardial infarction without increasing the risk of bleeding; and 3) compared with aspirin + clopidogrel, treatment with aspirin + new P2Y12 inhibitors may result in reduced risk of death.
Keywords: antithrombotic therapies, secondary prevention, acute coronary syndrome, network meta-analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]